DIABETIChESKAYa POLINEVROPATIYa: PODKhODY K TERAPII
- Authors: Azimova Y.E1
-
Affiliations:
- Issue: No 5 (2014)
- Pages: 100-103
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286765
- ID: 286765
Cite item
Open Access
Access granted
Abstract
Polyneuropathy is the most common form of neuropathy in diabetes mellitus. Management of patients with diabetic polyneuropathy includes glycemic control and other metabolic disorders, correction of risk factors, pathogenetic therapy aimed at slowing the progression of diabetic polyneuropathy, and symptomatic treatment of pain. One of the well-known means of pathogenetic therapy is α- lipoic acid; its effectiveness has been proven by several controlled trials and meta-analyzes. Safety of α- lipoic acid allows widely use of this drug in patients with diabetic polyneuropathy.
Keywords
Full Text
References
- Бондарь И.А., Королева Е.А. Альфа-липоевая кислота (Эспа-липон) - доказательства эффективности лечения диабетической нейропатии. Эффективная фармакотерапия. 2013; 22: 36-42.
- Недосугова Л.В. Альфа-липоевая кислота (Эспа-липон) в комплексном лечении диабетической нейропатии. Международный эндокринологический журнал. 2007; 8(2): 49-51.
- Arrieta F., Pinera M., Iglesias P. et al. Metabolic control and chronic complications during a 3-year follow-up period in a cohort of type 2 diabetic patients attended in primary care in the Community of Madrid (Spain). Endocrinol. Nutr. 2014; 61(1): 11-7.
- Cahn A, Elishuv O., Olshtain-Pops K. Establishing a multidisciplinary diabetic foot team in a large tertiary hospital: a Workshop. Diabetes Metab. Res. Rev. 2014; 20.
- Calles-Escandon J., Lovato L.C., Simons-Morton D.G., et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
- Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009; 360: 129-39.
- Han T., Bai J., Liu W., Hu Y. A systematic review and meta-analysis of a-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur. J. Endocrinol. 2012; 167: 465-71.
- McIlduff C., Rutkove S. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Therapeut. Clin. Risk Management. 2011; 7: 377-85
- Mijnhout G.S., Alkhalaf A., Kleefstra N., Bilo H.J. Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes? Neth. J. Med. 2010; 68(4): 158-62
- Pop-Busui R., Herman W.H., Feldman E.L., et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and naturalhistory. CurrDiab. Rep. 2010; 10: 276-82.
- Ziegler D., Hanefeld M., Ruhnau K.J., et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995; 38(12): 1425-33.
- Ziegler D., Hanefeld M., Ruhnau K.J., et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999; 22(8): 1296-301.
- Ziegler D., Low P.A., Litchy W.J., et al. Efficacy and safety of antioxidant treatment with a-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011; 34(9): 2054-60.
- Zychowska M., Rojewska E., Przewlocka B., Mika J. Mechanisms and pharmacology of diabetic neuropathy - experimental and clinical studies. Pharmacol. Rep. 2013; 65(6): 1601-10.
Supplementary files
